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Abstract
Background: The c-Myc oncogenic transcription factor heterodimerizes with Max, binds specific
DNA sites and regulates transcription. The role of Myc in transcriptional activation involves its
binding to TRRAP and histone acetylases; however, Myc's ability to activate transcription in
transient transfection assays is remarkably weak (2 to 5 fold) when compared to other
transcription factors. Since a deletion Myc mutant D106-143 and a substitution mutant W135E that
weakly binds TRRAP are still fully active in transient transfection reporter assays and the TATA
binding protein (TBP) has been reported to directly bind Myc, we sought to determine the effect
of TBP on Myc transactivation.
Results: We report here a potent stimulation of Myc transactivation by TBP, allowing up to 35-
fold transactivation of reporter constructs. Although promoters with an initiator (InR) element
briskly responded to Myc transactivation, the presence of an InR significantly diminished the
response to increasing amounts of TBP. We surmise from these findings that promoters containing
both TATA and InR elements may control Myc responsive genes that require brisk increased
expression within a narrow window of Myc levels, independent of TBP. In contrast, promoters
driven by the TATA element only, may also respond to modulation of TBP activity or levels.
Conclusion: Our observations not only demonstrate that TBP is limiting for Myc transactivation
in transient transfection experiments, but they also suggest that the inclusion of TBP in Myc
transactivation assays may further improve the characterization of c-Myc target genes.
Background
The c-myc oncogene is implicated in the genesis of many
human cancers and accounts for about 70,000 US cancer
deaths annually [1-3]. This oncogene produces the c-Myc
transcription factor, which heterodimerizes with Max via
the helix-loop-helix-leucine zipper (HLH-Zip) motif to
bind specific target DNA sequences and regulate transcrip-
tion [4-8]. The amino-terminal region of c-Myc, when
tethered to the yeast GAL4 DNA binding domain, behaves
as a potent transactivation domain (TAD) [9]. On the
other hand, the transactivation potential of native c-Myc
appears diminished when compared with other transcrip-
tion factors, such as the HLH-Zip protein USF1 or to the
GAL4 chimeric transactivators [10].
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The basis for the diminished transactivation potential of
c-Myc has remained elusive despite the discoveries that
the Myc activation domain specifically binds to factors
such as TRRAP [7,8,11-13]. TRRAP is a high molecular
weight, multifaceted molecule that is capable of recruiting
the histone acetyltransferase GCN5 [12]. The fact that c-
Myc is able to transactivate in Saccharomyces cerevisiae and
that yeast Tra1 is similar to TRRAP suggest that Myc's abil-
ity to transactivate in yeast may involve Tra1 [14,15]. The
c-Myc TAD encompasses two conserved regions, termed
Myc Box I and Myc Box II. Although Myc Box I does not
appear to affect transactivation, Myc Box II is required for
interaction with TRRAP. Although deletion of Myc Box II
renders Myc defective in binding TRRAP, it does not affect
the ability of Myc to transactivate specific promoter-
reporter constructs and in particular it does not affect the
ability of GAL4-Myc chimeric protein to transactivate [9].
In addition, deletion of Myc Box II appears to affect the
induction of certain endogenous target genes but not oth-
ers [16,17]. These observations suggest that transcrip-
tional regulation by Myc is likely to be manifold,
involving chromatin modulation as well as direct interac-
tion with components of the basal transcriptional
machinery [18-20]. This spectrum of activities allows Myc
to regulate subsets of genes that are more tightly control-
led and susceptible to chromatin modulation, whereas
other genes, such as the so-called "housekeeping" genes,
may already exist in open chromatin configuration and
hence may be regulated through recruitment of the basal
transcriptional machinery.
Searches for the interaction of c-Myc with components of
the transcriptional machinery have uncovered an interac-
tion with the coactivator CBP [21]. The C-terminal region
of Myc has been found to interact with SWI/SNF5 and
Miz-1, both implicated in transactivation and transrepres-
sion activities of Myc [22-27]. However, these activities
could not account for the transactivation potential of the
Myc N-terminal region (TAD). The interaction between
Myc and the TATA binding protein (TBP) has been
observed in diverse systems with evidence from intracellu-
lar chemical crosslinking, mammalian two-hybrid assay,
yeast two-hybrid assay, and GST fusion protein pull-down
assays [28-33]. In fact, two recent studies suggest that the
Myc TAD is consisted of a structureless N-terminal (Myc1-
88) portion connected by a linker followed by a C-terminal
(Myc92-167) partly helical domain, such that the two
domains are induced to adopt a specific conformation
upon binding TBP [31,32]. On the basis of these observa-
tions, we sought to determine in this study whether TBP is
limiting for Myc transactivation in transient transfection
experiments.
We sought to characterize the functional interaction of the
Myc TAD with TBP using the chimeric GAL4-Myc fusion
proteins as well as full-length Myc with four model pro-
moters (adenoviral major late promoter (AdML), lactate
dehydrogenase A (LDHA), CDK4 and ornithine decarbox-
ylase (ODC)) [34-37]. We found that addition of a TBP
expression vector in the transactivation assays increases
the transactivation by c-Myc from several fold to well over
30-fold [38]. By contrast, a GAL4-USF1 transactivator did
not respond to increasing input TBP. We also observe dif-
ferent responses by promoters that contain initiator (InR)
sequences versus promoters that only contain TATA ele-
ments [39-41]. Furthermore, a Myc Box II point mutation
W135E does not affect the ability of GAL4-Myc fusions to
synergize with TBP [42], but the deletion mutant D106-
143 has a blunted effect with cotransfected TBP. Our find-
ings not only support a functional interaction between c-
Myc and TBP, but they also provide a means to improve
transient transfection assays to study c-Myc target genes.
Results
TBP is limiting for GAL4-Myc transactivation
To determine whether TBP is limiting, we titrated the
GAL4-Myc transactivation assays with increasing amounts
of TBP plasmid. Although the GAL4-Myc chimera has sig-
nificant transactivation activity under the experimental
conditions chosen, addition of increasing amounts of TBP
plasmid resulted in a corresponding increase in transacti-
vation of GAL4-luciferase reporter (G5TATALuc) from
about 10 fold to over 60 fold with the highest amount of
TBP plasmid used (Fig. 1). TBP itself does not affect the
basal activity of G5TATALuc reporter, indicating that the
effect of TBP requires the presence of the GAL4-Myc chi-
mera. Further, the GAL4 DNA binding domain (GALO)
with minimal transactivation activity was not affected by
increasing TBP.
Since Myc Box II is necessary for interaction with TRRAP,
we sought to determine whether mutations in this region
affect the response of the Myc TAD to TBP. While the dele-
tion D106-143, which removes critical residues of Myc
BoxII, activates the reporter better than wild-type Myc
TAD, this deletion renders Myc TAD non-responsive to
increasing input TBP (Fig. 1). A substitution mutation in
Myc Box II, W135E, which was previously shown to have
diminished interaction with TRRAP and diminished
transformation activity [42,43], has a robust response to
increasing TBP. These results suggest that the entire region
comprising residues 106–143 is required for synergy with
TBP, whereas the transformation defective W135E mutant
still responds to increasing input TBP.
GAL4-Myc synergy with TBP is dependent on the TATA 
element
Since TBP was shown to be limiting for TATA-dependent
but not InR-dependent transcription [44], we sought to
determine whether GAL4-Myc cooperation with TBPBMC Biochemistry 2005, 6:7 http://www.biomedcentral.com/1471-2091/6/7
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TBP stimulates GAL4-Myc transactivation Figure 1
TBP stimulates GAL4-Myc transactivation. The reporter G5TATALuc contains five GAL4 binding sites followed by a minimal 
TATA box and the luciferase cDNA. Activator alone: the reporter was cotransfected with GAL4(1-147) DNA binding domain 
(GALO), GAL4 fused to Myc residues 1-262 (GM1-262), GM1-262 with residues 106–143 deleted (GM1-262D106), or GM1-
262 with a substitution of tryptophan 135 to glutamate (GMW135E) alone. TBP at increasing input plasmid amounts (µg indi-
cated on the abscissa) was cotransfected into CHO cells with the reporter alone (TBP) or with the indicated GAL4 plasmids. 
Bars are shown as averages with standard deviation (n = 10).
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requires the TATA element. We compared the response of
a GAL4 dependent reporter that is driven by an InR ele-
ment (G5INRLuc) with one that is driven by a TATA ele-
ment (G5TATALuc) (Fig. 2). In contrast to the TATA
TBP does not stimulate initiator driven luciferase reporter G5INRLuc that contains five GAL4 binding sites Figure 2
TBP does not stimulate initiator driven luciferase reporter G5INRLuc that contains five GAL4 binding sites. Either G5INRLuc 
or G5TATALuc (see Fig. 1) was cotransfected into CHO cells with GM1-262 alone or with increasing amounts of TBP (µg indi-
cated on the abscissa). For comparison, data points for G5TATALuc are the same as those shown in Fig. 1. Note that TBP does 
not stimulate GAL4Myc transactivation of G5INRLuc; there is a slight inhibition by TBP. Bars are shown as averages with 
standard deviation (n = 4).
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driven reporter, the InR-driven reporter responded more
briskly to GAL4-Myc but the reporter activity did not fur-
ther increase with TBP. This observation suggests that the
Myc TAD activates InR dependent transcription, for which
TBP is not limiting.
TBP is not limiting for USF1 TAD
To determine whether the effect of TBP is selective, we
compared the ability of the USF1 TAD with the Myc TAD
to synergize with TBP. USF1 is a transcription factor that
also belongs to the HLH-Zip family and either
homodimerizes or heterodimerizes with USF2. The USF
family members binds to DNA target sites (5'-CACGTG-
3') that appear indistinguishable from Myc targets,
though Myc is capable of binding additional non-canoni-
cal sites. To eliminate the effects of the USF1 and Myc
DNA binding domains on transcription, we sought to
study chimeras of GAL4 with USF1 or Myc TADs.
Although the GAL4-USF1 chimera activates G5-TATA-Luc
as effectively as GAL4-Myc, TBP did not further increase
the activity of GAL4-USF1 (Fig. 3). This observation sug-
gests that while USF1 and Myc may have overlapping tar-
get DNA binding sequences, their TADs appear distinctly
different, particularly in response to the addition of TBP.
Effects of TBP on full-length wild-type and mutant c-Myc 
transactivation of the LDHA promoter
Having observed a TATA-dependent synergy between TBP
and the Myc TAD in the chimeric GAL4 system, we sought
to determine whether TBP could stimulate Myc transacti-
vation of target gene promoters. We first chose the LDHA
promoter that comprises two canonical E-boxes located
about 100 and 200 bp upstream of the transcriptional
start site [36]. We used an amount of input MLV-LTR-
driven Myc expression vector that only minimally
increased LDHA promoter activity to study the effects on
increasing input TBP. TBP increased wild-type Myc activity
from only about 20 % to about 800 % increase (Fig. 4).
TBP alone, without added Myc, slightly increased reporter
activity to about 2-fold. Note that the empty MLV LTR
plasmid caused a slight increase in reporter activity, which
was not accentuated by the addition of TBP.
We also studied two Myc mutants in the context of addi-
tional TBP (Fig. 4). The Myc dHLH mutant lacks the helix-
loop-helix domain, and therefore neither dimerizes with
Max nor binds DNA. The dHLH mutant minimally affects
basal promoter activity and was not affected by increasing
input TBP. The W135E mutant contains a substitution in
the Myc Box II domain that renders Myc deficient in trans-
formation [42,43]. Intriguingly, W135E was active and
fully responsive to increasing TBP.
Because transient transfection reporter assays are con-
founded by many factors, we sought to assure that the syn-
ergistic transactivation of the LDHA promoter by Myc and
TBP is dependent on Myc binding. We compared the
response of the wild-type LDHA promoter (LDH Luc)
with one in which both E-boxes are mutated (LDH DM
Luc) so that Myc could not bind these sites (Fig. 5). The
mutant LDH DM Luc displayed no increase in reporter
activity with increasing amounts of TBP in contrast to the
wild-type LDH Luc. This result confirms that the synergy
between TBP and Myc is dependent on the Myc binding
sites in the LDHA promoter.
The effect of the initiator (InR) element on the synergy 
between Myc and TBP
We have previously studied the adenoviral major late
(AdML) promoter as a model Myc responsive promoter
that contains both InR and TATA elements [37]. Others
and we have shown that c-Myc regulation of the AdML is
biphasic with transactivation followed by transrepression
at high levels of input Myc plasmids [37,45]. The transac-
tivation phase depends on E-boxes, whereas the transre-
pression phase depends on the InR. Here we chose the
AdML promoter to determine the effect of the InR on the
synergy between Myc and TBP.
As compared with the LDHA promoter, which increased
in activity with increasing input TBP, the AdML promoter
briskly increased activity in response to Myc alone but did
not further increase with TBP (Fig. 6). Mutation of the InR
element in AdML promoter renders it much less
responsive to Myc, but addition of TBP resulted in a
marked increase in promoter activity. These observations
suggest that the InR increases promoter response to Myc
alone, but the InR renders the promoter independent of
increasing TBP. Hence, it may be surmised that the com-
bination of E-boxes and InR may be optimal for promot-
ers that require sharp response to Myc regulation, since
TBP would not be limiting.
Synergy of Myc and TBP with CDK4 and ODC responsive 
sequences
We selected the CDK4 promoter, which contains four
canonical E-boxes and no InR element, and the intronic
ODC tandem E-box sequence to determine the extent of
synergy between Myc and TBP. The CDK4 promoter
responded to Myc as previously reported. Increasing input
TBP further caused a 30-fold activation of the CDK4 pro-
moter as compared to 5-fold activation with Myc alone
(Fig. 7). The synergy between Myc and TBP is dependent
on Myc binding, since the E box mutant CDK4 promoter
is not responsive to the combination of Myc and TBP.
ODC, the prototypical Myc responsive gene, provides a
different model that utilizes intronic Myc binding sites.
The ODCLuc reporter comprises the ODC promoter and
intronic E boxes with flanking sequences. Compared toBMC Biochemistry 2005, 6:7 http://www.biomedcentral.com/1471-2091/6/7
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TBP does not stimulate the activation of G5TATALuc by GAL4USF1 Figure 3
TBP does not stimulate the activation of G5TATALuc by GAL4USF1. For comparison, the stimulation of G5TATALuc by 
GAL4Myc (GM1-262) and TBP is shown. By contrast increasing amounts of TBP (µg indicated on the abscissa) does not 
increase reporter activity that is stimulated by USF TAD. Bars are shown as averages with standard deviation (n = 4). Plasmids 
were transfected into CHO cells.
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Activation of the lactate dehydrogenase A promoter construct (LDHLuc) by Myc is increased by TBP Figure 4
Activation of the lactate dehydrogenase A promoter construct (LDHLuc) by Myc is increased by TBP. Activator alone: cotrans-
fection with LDHLuc and MLV-LTR driven Myc expression vectors: MLV, empty expression vector; Myc, wild-type Myc; dHLH, 
helix-loop-helix deletion mutant D371-412; W135E, substitution mutant with glutamate replacing tryptophan 135. Increasing 
amounts of TBP (µg indicated on the abscissa) was cotransfected with Myc and reporter constructs. Bars are shown as aver-
ages with standard deviation (n = 10). Transfections were performed using NIH 3T3 cells.
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Myc DNA binding sites in the LDHA promoter construct (LDHLuc) is required for TBP stimulation of Myc-mediated  transactivation Figure 5
Myc DNA binding sites in the LDHA promoter construct (LDHLuc) is required for TBP stimulation of Myc-mediated transac-
tivation. Wild-type LDHLuc or a mutant promoter construct (LDHDMLuc), which has both Myc E-boxes mutated from 5'-
CACGTG-3' to 5'-CCCGGG-3', were cotransfected with a constant amount of MLV-LTR driven wild-type c-myc plasmid and 
increasing amounts of TBP (µg indicated on the abscissa). Bars are shown as averages with standard deviation (n = 6). Transfec-
tions were performed using NIH 3T3 cells.
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The initiator element in the adenoviral major late promoter luciferase construct (pGLMLP Luc) increases the response to Myc  but does not allow further stimulation by TBP Figure 6
The initiator element in the adenoviral major late promoter luciferase construct (pGLMLP Luc) increases the response to Myc 
but does not allow further stimulation by TBP. Compared with the reporter containing a mutant InR (pGLMLP dINR Luc), 
which displays a highly synergistic stimulation by Myc and TBP, the wild-type pGLMLP Luc construct briskly responds to Myc 
independent of increasing amounts of TBP (µg indicated on the abscissa). Bars are shown as averages with standard deviation 
(n = 10). Transfections were performed using NIH 3T3 cells.
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the LDHA promoter, which displayed about an 8 fold
induction, ODCLuc responded to TBP and Myc with a 35-
fold induction (Fig. 8). With this robust response, we
sought to determine the response of ODCLuc to Myc and
Activation of the human CDK4 promoter (CDK Luc) by Myc is further stimulated by increasing amounts of TBP (µg indicated  on the abscissa) Figure 7
Activation of the human CDK4 promoter (CDK Luc) by Myc is further stimulated by increasing amounts of TBP (µg indicated 
on the abscissa). The synergy between Myc and TBP is dependent on the Myc binding sites, which are mutated in the reporter 
CDK EMut Luc. Bars are shown as averages with standard deviation (n = 6). Transfections were performed using NIH 3T3 
cells.
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TBP mutants (Fig. 9). In this experiment, ODCLuc was co-
transfected with a constant amount of Myc and the maxi-
mal amount of input TBP. Whereas wild-type TBP stimu-
lated ODCLuc, all TBP mutants studied had virtually no
Activation of the ornithine decarboxylase (ODC) intronic E-boxes driven luciferase reporter (ODC Luc) by Myc is further  stimulated by TBP (µg indicated on the abscissa) Figure 8
Activation of the ornithine decarboxylase (ODC) intronic E-boxes driven luciferase reporter (ODC Luc) by Myc is further 
stimulated by TBP (µg indicated on the abscissa). The relative marked stimulation of the ODC sequences by Myc and TBP is 
compared with the more diminished stimulation of the LDHA promoter (LDH Luc) previously shown in Fig. 4. Bars are shown 
as averages with standard deviation (n = 10). Transfections were performed using NIH 3T3 cells.
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activity (Fig. 9). The lack of activity of TBP mutants defec-
tive in TATA binding or Pol II interactions was expected;
however, we are intrigued by the lack of apparent activity
of the Pol III defective TBP mutants. Further studies will
be necessary to define the molecular basis for the lack of
synergy between Myc and these various TBP mutants. We
conclude however, that wild-type TBP is necessary for syn-
ergy with Myc in the transactivation of ODC Luc.
Discussion
Myc's dramatic biological effects, a plethora of well-char-
acterized interactions between Myc and other proteins, an
ever-expanding list of putative target genes and a seem-
ingly weak transactivation potential characterize the
enigma of c-Myc-mediated gene regulation [4,46]. Com-
pared with other more potent transactivators, especially in
the same family of HLH-Zip proteins, c-Myc stimulates
reporter constructs only 2- to 5-fold in an E-box depend-
ent manner. The basis for this apparently weak transacti-
vation is poorly understood. We report in this paper a
strong synergy between Myc and TBP resulting in up to
35-fold induction of reporter plasmids. Our observations
indicate that TBP is limiting for Myc transactivation and
Synergy between Myc and TBP to activate ODC Luc (see Fig. 8) is diminished by mutations in TBP that inhibits TATA box  binding (TATA def), interaction with RNA polymerase II (pol2 def) or interaction with RNA polymerase III (pol3 def) Figure 9
Synergy between Myc and TBP to activate ODC Luc (see Fig. 8) is diminished by mutations in TBP that inhibits TATA box 
binding (TATA def), interaction with RNA polymerase II (pol2 def) or interaction with RNA polymerase III (pol3 def). Myc (1 
µg) was cotransfected with ODC Luc and 4 µg of wild-type or mutant TBP constructs. Bars are shown as averages with stand-
ard deviation (n = 4). Transfections were performed using NIH 3T3 cells.
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provide a means to enhance the characterization of Myc
target genes.
The weak transactivation potential of c-Myc may well be
biologically significant when the degree of gene induction
by c-Myc is considered [8]. The emergence of an increas-
ing number of Myc target genes reveals several character-
istics among the genes. With only a few exceptions, Myc
induces endogenous genes by only a few fold above back-
ground. In multiple instances, it appears that the broad-
based effect of inducing multiple genes in the same path-
way by c-Myc may be more important than the marked
induction of a few genes [7,47]. Perhaps c-Myc globally
affects gene expression through multiple mechanisms.
The connection between c-Myc and histone acetylation
has become more firmly established, suggesting a role for
Myc to modulate chromatin [47-51]. Beyond chromatin
modulation, the role of Myc in transcriptional initiation
or elongation is less well understood. Searches for an
interaction between Myc and members of the general
transcription factors have revealed an interaction between
the Myc transactivation domain and TBP [31]. In the work
reported here, we provide evidence for a functional inter-
action between Myc and TBP in transient transfection
reporter assays. Although the addition of TBP dramati-
cally enhances these assays, the biological significance of
this synergism is not delineated in our study. In particular,
since many Myc target genes are induced only several fold
in vivo, the role of TBP in modulating these target genes in
vivo is not at all clear.
In response to TBP and Myc, promoters with an initiator
element respond differently compared with those with a
TATA element only [39-41]. With both the GAL4 chimeric
proteins and full length Myc, InR driven promoters
respond to the Myc TAD briskly. However, the increase in
TBP did not further augment the activities of InR driven
promoters. These observations are consistent with previ-
ous findings that TBP is limiting for TATA driven, but not
InR driven promoters in Drosophila [44]. It is intriguing to
note the initial brisk response of InR containing promot-
ers to Myc, which at high levels can inhibit the same InR
driven promoters. We surmise from these findings that
promoters comprising both TATA and InR elements may
control Myc responsive genes that require brisk increased
expression within a narrow window of Myc levels inde-
pendent of TBP. Such genes would be sharply induced by
Myc, which in excess can inhibit the same genes through
the InR [37,45].
In contrast to InR containing promoters, promoters with
TATA element only, such as CDK4 and LDHA, increase in
activity with increasing TBP levels in the presence of a con-
stant amount of Myc. These promoters may be regulated
by the activity of TBP in vivo, although evidence for this is
lacking. The observation that oncogenic Ras can augment
TBP activity suggests that a subset of Myc target genes may
also be further responsive to increased TBP through acti-
vated oncogenic Ras [52]. In fact, Myc and Ras can coop-
erate to regulated cdc2 [53]. Hence, it will be instructive to
determine the set of Myc responsive genes versus the set of
genes that are responsive to both Myc and Ras. Compari-
son of promoters or regulatory regions of these genes are
likely to uncover a level of transcriptional complexity pre-
viously unappreciated.
The fact that the synergy between TBP and Myc was
observed with the GAL4 chimeric activator system and full
length Myc suggests that the synergy is mediated through
the Myc transactivation domain. Furthermore, the Myc
Box II deletion mutant D106-143 was unresponsive to
increasing TBP, indicating that this region of Myc is
required for synergy with TBP. This observation is consist-
ent with the previous finding that in vitro interaction
between Myc and TBP requires Myc Box II [28]. Although
we observed a significant synergy between Myc and TBP,
none of the TBP mutants retained any synergistic activity.
It is not surprising that both TATA box binding mutant
and Pol II interaction defective TBP mutants were
dysfunctional. Although it may seem surprising that Pol
III interaction defective TBP mutants were also inactive,
recent studies suggest a significant overlap between Pol II
and Pol III interactions with TBP [38]. Although beyond
the scope of the current study, it will be of significant
interest to map the regions of TBP required for the
interaction with Myc and correlate this with the ability for
TBP mutants to synergize with Myc.
Conclusion
In summary, we describe in this report a significant stim-
ulation of Myc transactivation by TBP. However, the pres-
ence of an InR diminishes the promoter response to TBP.
We surmise that these differences may be exploited in vivo
to increase the complexity and range of gene regulation by
Myc.
Methods
Plasmids
GAL4 constructs were as described [9]. GAL4-MycW135E
(GMW135E) is GAL4(1-262) in which the Pst1-Pst1 frag-
ment was exchanged with a fragment containing the sub-
stitution W135E from full length c-myc in MLVMycW135E
[43]. GAL4-USF1 was constructed by inserting a PCR-
amplified, sequence-verified 560-bp USF1 fragment
(corresponding to residues 1–180) into the NdeI-BstEII
sites of pGALm. The USF1 cDNA template for PCR was a
gift from M. Sawadogo and R. Roeder [10]. The Gal4
TATA-driven reporter G5TATALuc was constructed from
G5TATA-CAT(gift from M. Green) by replacing CAT withBMC Biochemistry 2005, 6:7 http://www.biomedcentral.com/1471-2091/6/7
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luciferase (Luc) [54]. The Gal4 InR-driven G5INRLuc
reporter (gift from J. Gralla) was as described [55].
Murine sarcoma virus long terminal repeat (MSV-LTR)
promoter driven wild-type and mutant TBP expression
vectors were gifts from A. Berk and are as described [56].
Expression vectors for wild-type and mutant c-myc are as
described [43].
The reporter ornithine decarboxylase ODC-Luc is a gift
from J. Cleveland [35]. The wild-type and mutant lactate
dehydrogenase promoter LDH-Luc reporters were previ-
ously described [36]. Wild-type and mutant adenoviral
major late promoter AdML-Luc constructs were previously
reported [37]. Wild-type and mutant cyclin dependent
kinase CDK4-Luc was described [34].
Cell culture and transfection
Chinese Hamster Ovary (CHO) cells were grown in 5%
CO2 at 37°C in α MEM
(LTI) supplemented with 10% fetal bovine serum (LTI)
and antibiotics as described [9]. Cells were transiently
transfected using DEAE-dextran (0.275 mg/ml). Two µg of
GAL4 reporter luciferase plasmid, two µg of GAL4 chi-
meric activator plasmid and increasing amounts of
pLTRTBP (0.5 to 4 µg) were cotransfected into 100 mm
plates of 60% confluent CHO cells. DNA concentration
was maintained at 8 µg by the addition of pLTR empty
vector. Cells were incubated with the DNA in serum-free
DEAE-dextran/MEM media overnight. Cells were
harvested 48 hours after DMSO/ chloroquine shock and
assayed for luciferase activity as described.
NIH3T3 cells (gift from R. Eisenman) were grown in 5%
CO2 at 37°C in DMEM (low glucose) (LTI) supple-
mented with 10% fetal bovine serum and antibiotics.
Cells were transfected with Lipofectin (LTI). Lipofectin
was added at 5 X the total concentration of DNA to serum-
free Opti-MEM media (LTI) and incubated at room tem-
perature for 45 min. Two µg of various promoter-reporter
luciferase plasmid and one µg of full-length wild-type or
mutant c-myc activator plasmid were added with increas-
ing amounts of pLTRTBP (0.5 to 4 µg) to the Opti-MEM/
Lipofectin mixture. DNA concentrations were maintained
at 7 µg by adding pLTR empty vector. The Opti-MEM/
Lipofectin/ DNA mixture was incubated at room temper-
ature for 10 min. then added to 100 mm plates of 30%
confluent NIH3T3 cells. Cells were incubated for 5 hours,
aspirated and fed fresh media and harvested after 48
hours for luciferase activity.
Luciferase assay
Luciferase activity was measured using the luciferase assay
system according to manufacturer's instructions
(Promega). Cells were washed in phosphate buffered
saline (PBS), scraped using Cell Lysis Solution (Promega)
and centrifuged for 2 min at 1000 rpm. Luciferin cocktail
(80 µl) was added to 20 µl lysate and luciferase activity
was measured in a luminometer. Samples were run in
duplicate.
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